Background and Objectives: We used virtual histology-intravascular ultrasound (VH-IVUS) to evaluate the relationship between high-sensitivity C-reactive protein (hs-CRP) levels and plaque components in 279 acute coronary syndrome (ACS) patients. Subjects and Methods: We divided patients into three groups according to their hs-CRP levels {lowest tertile <0.07 mg/dL (n=93), middle tertile ≥0.07, <0.4 mg/dL (n=93), and highest tertile ≥0.4 mg/dL (n=93)}. Thin-cap fibroatheroma (TCFA) was defined as focal, necrotic core (NC)-rich (≥10% of the cross-sectional area) plaques in contact with the lumen in a plaque burden ≥40%. Results: The highest tertile group was mostly diabetics (20%, 27%, 40%, p=0.009), and had the greatest plaque plus media volume (163±139/mm 3 vs. 201±155/mm 3 vs. 232±176/mm
Introduction
Vascular inflammation plays a pivotal role in atherogenesis and thrombotic events. 1) High-sensitivity C-reactive protein (hs-CRP) has been associated with metabolic syndrome 2) and with elevated risks for the development of coronary artery disease.
3) hs-CRP has emerged as a simple tool for detecting systemic inflammation in patients with subsequent coronary events. 4) Measurement of hs-CRP has been recommended for patients to refine risk assessment. 5) Several grey-scale intravascular ultrasound (IVUS) studies have demonstrated increased incidence of culprit-lesion plaque rupture in patients with acute coronary syndrome (ACS). [6] [7] [8] There is a strong inflammatory response to tissue injury that occurs during ACS, and plaque rupture and the extent of inflammatory response may be an important determinant of clinical outcome. 9) Several studies have reported that CRP elevation was associated with culprit lesion plaque rupture in ACS patients. 6 )7)10) Recently, several virtual histology (VH)-IVUS studies have demonstrated coronary plaque components in ACS patients.
11)12)
In spite of the strong association between CRP levels and vulnerable plaque using grey-scale IVUS, no studies have demonstrated a relationship between inflammatory response indicated by CRP, and plaque characteristics in ACS patients. Therefore, the aim of this study was to assess the relationship between hs-CRP levels and plaque characteristics, including plaque composition, and the incidence of thin-cap fibroatheroma (TCFA) in ACS patients.
Subjects and Methods

Patient population
This study was a retrospective, single-center study. From July 2007 to June 2008, 279 consecutive ACS patients who underwent VH-IVUS for native, de novo coronary lesions and underwent pre-procedural hs-CRP evaluation were included in this study. We divided patients into three groups according to their pre-procedural hs-CRP levels {lowest tertile <0.07 mg/dL (n=93), middle tertile ≥0.07, <0.4 mg/dL (n= 93), and highest tertile >0.4 mg/dL (n=93)}. The presence of unstable angina was determined by chest pain within the preceding 72 hours with or without ST-T-wave changes, or positive cardiac biochemical markers (creatine kinase-myocardial band or cardiac specific troponin-I). The presence of ST-segment elevation myocardial infarction was determined by >30 minutes of continuous chest pain, new ST-segment elevation ≥2 mm on at least 2 contiguous electrocardiographic leads, and creatine kinase-MB (CK-MB) >3 times the normal limit. The presence of non-ST-segment elevation myocardial infarction was diagnosed by chest pain, and positive cardiac biochemical markers (creatine kinase-myocardial band or cardiac specific troponin-I) without new ST-segment elevation. The protocol was approved by the institutional review board. Hospital records of patients were reviewed to obtain information on clinical demographics.
Laboratory analysis
Venous blood samples were obtained before the IVUS study within 24 hours of symptom onset. Blood samples were centrifuged, and serum was removed and stored at -70°C until the assay could be performed. hs-CRP was assessed by the immunoturbidimetric CRP-Latex (II) hs assay using an Olympus 5431 autoanalyzer. The assay was performed according to the manufacturer's protocol, and has been validated against the Dade-Behring method. 13) This assay has a coefficient of variation of 5%. Serum N-terminal pro-B-type natriuretic peptide was measured using an electrochemiluminescence sandwich immunoassay method with an Elecsys 2010 analyzer (Roche Diagnostics, Mannheim, Germany). Absolute CK-MB levels were determined by radioimmunoassay (Dade Behring Inc., Miami, FL, USA). Cardiac-specific troponin I levels were measured by paramagnetic particle, chemiluminescent immunoenzymatic assay (Beckman, Coulter Inc., Fullerton, CA, USA). The serum levels of total cholesterol, triglyceride, low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein cholesterol were measured by standard enzymatic methods.
Angiographic analysis
Coronary angiogram was analyzed with a validated quantitative coronary angiography (QCA) system (Phillips H5000 or Allura DCI program, Philips Medical Systems, Eindhoven, the Netherlands). The outer diameter of the contrastfilled catheter was the calibration standard. Minimal lumen and reference diameters were measured in diastolic frames from orthogonal projections.
Intravascular ultrasound imaging and analysis
All pre-intervention grey-scale and VH-IVUS examinations were performed after intracoronary administration of 300 μg nitroglycerin. A 20-MHz, 2.9F IVUS imaging catheter (Eagle Eye, Volcano Corp, Rancho Cordova, CA, USA) was advanced >10 mm beyond the lesion. Automated pullback was performed to a point >10 mm proximal to the lesion at a speed of 0.5 mm/sec.
Quantitative volumetric grey-scale and VH-IVUS analyses were performed across the entire lesion segment, and crosssectional analysis was performed at the minimum lumen sites. Conventional quantitative volumetric grey-scale IVUS analysis was performed according to the American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies. 14) External elastic membrane (EEM) and lumen cross-sectional areas (CSAs) were measured. Plaque plus media (P&M) CSA was calculated as EEM minus lumen CSA. Plaque burden was calculated as P&M divided by EEM CSA. Proximal and distal references were the single slices with the largest lumen and smallest plaque burden within 10 mm proximally and distally, but before any large side branch. VH-IVUS analysis classified color-coded tissue into four major components: green (fibrotic); yellow-green (fibro-fatty); white (dense calcium); and red (necrotic core, NC) ( Fig. 1) .
11)15) VH-IVUS analysis was reported in absolute quantity, and as a percentage of the plaque area or volume. TCFA was defined as NC ≥10% of plaque area in at least 3 consecutive frames without overlying fibrous tissue, in the presence of ≥40% plaque burden.
11)
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) for Windows, version 15.0 (Chicago, IL, USA) was used for all analyses. Continuous variables were presented as mean±SD; comparisons were conducted by Student's t-test or the Wilcoxon rank-sum test if normality assumption was violated. Discrete variables were presented as percentages and frequencies. Comparisons were conducted by chi-square statistics or Fisher's exact test as appropriate. Multivariable analysis was performed to identify independent predictors of hs-CRP elevation (≥0.4 mg/dL), and culprit lesion TCFA. A p< 0.05 was considered statistically significant.
Results
Patient characteristics
Patient baseline characteristics are summarized in Table 1 . Mean hs-CRP levels were 0.04 mg/dL in lowest tertile group, 0.19 mg/dL in middle tertile group, and 1.85 mg/dL in highest tertile group. Ejection fraction was lowest, N-terminal pro-B-type natriuretic peptide, white blood cell count, glucose, low-density lipoprotein cholesterol, and triglyceride levels were highest, hemoglobin level was lowest, and CK-MB and 
Angiographic findings
Angiographic findings are summarized in Table 2 . There were no significant differences in the culprit vessel, lesion location, the incidences of multivessel disease, Thrombolysis in Myocardial Infarction flow grade, and reference diameter between three groups. However, minimal lumen diameter was smallest in the highest tertile group.
Grey-scale intravascular ultrasound results
Grey-scale IVUS findings are summarized in Table 3 . There were no significant differences in the IVUS parameters at the proximal and distal references. At the minimum lumen sites, P&M CSAs were greatest and IVUS lesion length was longest in the highest tertile group. Plaque rupture and multiple plaque ruptures were observed most frequently in the highest tertile group (28% vs. 36% vs. 51%, p<0.001, and 15% vs. 22% vs. 30%, p=0.014, respectively). By volumetric analysis, EEM, lumen, and P&M volumes were greatest in the highest tertile group.
Virtual histology-intravascular ultrasound results
At the minimum lumen sites, absolute and %NC areas were greatest in the highest tertile group (Fig. 2) . By volumetric analysis, absolute and %NC volumes were greatest in the highest tertile group (Fig. 3) . The TCFA within culprit lesions was observed most frequently in the highest tertile group (Fig. 4) .
Independent predictors of high-sensitivity C-reactive protein elevation and thin-cap fibroatheroma
Multivariate analysis was performed to identify independent predictors of hs-CRP elevation. Variables with p<0. dependent predictors of hs-CRP elevation.
We performed multivariate analysis to determine independent predictors of culprit lesion TCFA. All variables with p< 0.2 in the univariate analysis (age, male gender, diabetes mellitus, hypertension, smoking, ejection fraction, hs-CRP, and P&M volume) were evaluated for multivariate analysis. Diabetes mellitus (OR: 2.14, 95% CI: 1.30-3.60, p=0.008) and the hs-CRP (OR; 1.86, 95% CI=1.11-2.90, p=0.010) were independent predictors of TCFA.
Discussion
The present VH-IVUS study demonstrated that 1) the highest hs-CRP tertile group has the most diabetics, and had the greatest P&M volume as well as absolute and % NC volumes; 2) the culprit lesion TCFA was observed most frequently in the highest hs-CRP tertile group; 3) absolute NC volume was an independent predictor of hs-CRP elevation; and 4) the hs-CRP was an independent predictor of TCFA.
CRP has emerged as a simple tool for detecting systemic inflammation. 4) An elevated CRP level is associated with increased risk of future fatal or non-fatal ischemic complications in ACS patients. 16)17) A previous study demonstrated that CRP was strongly associated with atherosclerosis measured at various sites in the arterial tree.
18) Several mechanisms have been described through which CRP and other inflammatory mediators may be actively involved in atherogenesis. 19) CRP is produced by smooth muscle cells of atherosclerotic lesions, 20) and locally produced CRP could directly participate in atherogenesis and the development of cardiovascular complications.
Pathological studies have demonstrated that plaque rupture and subsequent thrombosis is the most important mechanism leading to ACS. 21)22) Several grey-scale IVUS studies have demonstrated the association between CRP and vulnerable plaque in ACS patients. 6)7)10) Sano et al. 6) reported that patients with elevated CRP levels had more plaque ruptures, compared with those with a normal CRP, and that plaque rupture correlated with elevated CRP level in the setting of AMI. Hong et al. 7) reported that elevated CRP level was an independent predictor of plaque rupture in AMI patients using a 3-vessel IVUS. Tanaka et al. 10) reported that AMI patients with culprit lesion plaque ruptures presented with higher CRP levels, as compared with AMI patients without plaque rupture. The number of plaque ruptures correlated with CRP levels one month from onset.
VH-IVUS has the potential to provide detailed qualitative and quantitative information, and it can help identify four specific plaque components. Plaque components may play a role in plaque disruption and thrombosis that lead to acute coronary events.
23)24) Lesions with a large lipid core may present higher risk of disruption than sclerotic plaques. 25)26) TCFA is the precursor of plaque rupture, which accounts for a majority of coronary thrombi and coronary death.
23)27)28) Several VH-IVUS studies have reported that ACS patients had more NC-containing plaques, and more TCFAs compared with stable angina patients. 11)12) Burke et al. 29) reported correlation between CRP and the number of TCFAs in patients who experienced sudden death associated with severe coronary artery disease. In the present study, the NC component was greatest, and TCFA within culprit lesions was observed most frequently in patients with the highest hs-CRP tertile, and there existed a correlation between hs-CRP levels vs. NC components and TCFA, and cardiac enzyme levels were significantly higher after stenting in patients with TCFA, compared with patients without TCFA {∆(poststenting-baseline value) CK-MB: +10.1±22.0 U/L vs. -3.8±26.1 U/L, p=0.012; ∆cardiac-specific troponin I: +8.3±15.5 ng/mL vs. -0.9±11.4 ng/mL, p= 0.021}. The present study suggests that hs-CRP is associated with the development of vulnerable plaque in ACS patients. The NC components contain foam cells with lipid deposition, inflammatory cells, intramural bleeding, and cholesterol crystals. As such, they may be associated with CRP elevation in ACS patients.
There are several limitations to be mentioned. First, the present study is a retrospective single-center study and is subject to limitations inherent in this type of clinical investigation. Second, IVUS and VH-IVUS were performed at the discretion of individual operators leading to potential selection bias. Third, we did not attempt to differentiate between atherosclerotic plaque and thrombus, because VH-IVUS could not determine the presence of thrombus. This may obscure the identification of TCFA.
Fourth, heavily calcified plaques may induce an artifact regarding the codification of plaques by VH-IVUS, resulting in increased NC content. Fifth, serial follow-up of serum hs-CRP level was not performed. Therefore, we did not demonstrate the impact of sequential change of hs-CRP levels on plaque components.
In conclusion, ACS patients with elevated hs-CRP have more vulnerable plaque components (NC-rich plaques and higher frequency of culprit lesion TCFA), compared with ACS patients with normal hs-CRP.
